Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector

Gene Therapy

Volumn 3, Issue 6, 1996, Pages 496-502

  Smith, T A G ^a   White, B D ^a   Gardner, J M ^a   Kaleko, M ^a   McClelland, A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus vector; Repeat dosing; Transient immunosuppression

Indexed keywords

15 DEOXYSPERGUALIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GUANIDINES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LAC OPERON; MICE; MICE, INBRED C57BL; TRANSFECTION;

EID: 0029934048     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Yei S et al. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994; 5: 731-744.
2. Engelhardt JF et al. Adenovirus-mediated transfer of the CFTR gene to the lung of nonhuman primates: biological efficacy study. Hum Gene Ther 1993; 4: 759-769
3. Smith TAG et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5. 397-402.
4. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
5. Kozarsky KF et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
6. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994, 91: 2353-2357.
7. Yei S et al Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy 1994; 1: 192-200.
8. McElvaney NG, Crystal RG. IL-6 release and airway administration of human CFTR cDNA adenovirus vector. Nature Med 1995; 1: 182-184.
9. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
10. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
11. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
12. Connelly S et al. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: (in press).
13. Alegre M et al. Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 1994; 57: 1786-1794.
14. Willers JMN, Sluis E The influence of cyclophosphamide on antibody formation in the mouse. Ann Immunol (Inst Pasteur) 1975; 126C: 267-279.
15. Pukhalsky AL, Toptygina P, Viktorov VV. Immunosuppressive action of cyclophosphamide in mice: contribution of some factors to determination of strain differences. Int J Immunopharm 1993; 15: 509-514.
16. Suzuki S. Deoxyspergualin: mode of action and clinical trials. Ann NY Acad Sci 1993; 696: 263-269.
17. Jindal RM, Tepper MA, Soltys K, Cho SI. Deoxyspergualin - a novel immunosuppressant. Mt Sinai J Med 1994; 61: 51-56.
18. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
19. Wilson C, Kay MA. Immunomodulation to enhance gene therapy. Nature Med 1995; 1: 887-889.
20. Fang B et al. Gene therapy for hemophilia: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
21. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration Nat Genet 1995; 11: 191-197.
22. Tepper MA. Deoxyspergualin: mechanism of action studies of a novel immunosuppressive drug. Ann NY Acad Sci 1993; 696: 123-132.
23. Tufveson G, Gannedahl G. Deoxyspergualin - a different and intriguing immunosuppressant. Transplant Proc 1994; 26: 3029-3039.
24. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hemat 1994; 47: 208-217.
25. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. New Engl J Med 1988; 318: 947-950.
26. Mittal SK, Prevec L, Graham FL, Babiuk LA. Development of a bovine adenovirus type 3-based expression vector. J Gen Virol 1995; 76: 93-102.
27. Shenk T, Williams J. Genetic analysis of adenovirus. Curr Top Microbiol Immunol 1984; 111: 1-39.
28. Maizel JV, White DO, Scharff MD. The polypeptides of adenovirus I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115-125.
29. Connelly S, Gardner JM, McClelland A, Kaleko M. High level tissue-specific expression of functional human factor VIII in mice Hum Gene Ther 1996; 7: 183-195.
30. Jallat S et al. Characterization of recombinant human factor IX expressed in transgenic mice and in derived transimmortalized hepatic cell lines. EMBO J 1990; 9: 3295-3301.
31. Connelly S et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-193.